SLC5A2 and chronic kidney disease: We illustrate the method by determining how knowledge of acute change in estimated glomerular filtration rate modifies the expected effect of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on clinical endpoints in patients with chronic kidney disease.